FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutics and concerns irinotecan liposomes or its hydrochloride containing irinotecan or its hydrochloride, neutral phospholipid and cholesterol, wherein the weight ratio of cholesterol to neutral phospholipid makes 1:3-5, and a method for preparing them.
EFFECT: liposomes have higher stability.
15 cl, 3 dwg, 10 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LIPOSOMAL PHARMACEUTICAL PREPARATION AND METHOD FOR PREPARING IT | 2007 |
|
RU2494729C2 |
| NEW LIPOSOME COMPOSITIONS | 2006 |
|
RU2454229C2 |
| APPLICATION OF MITOXANTHONE HYDROCHLORIDE LIPOSOM FOR THE TREATMENT OF BREAST CANCER | 2021 |
|
RU2806277C1 |
| USE OF MITOXANTHRON LIPOSOME FOR THE TREATMENT OF NON-HODGKIN'S LYMPHOMA | 2019 |
|
RU2804477C2 |
| PHARMACEUTICAL COMPOSITION FOR TREPOSTINIL CONTROLLED RELEASE | 2019 |
|
RU2796305C2 |
| LIPOSOME HAVING INNER AQUEOUS PHASE AND CONTAINING SULPHOBUTYL ESTER CYCLODEXTRIN SALT | 2010 |
|
RU2575793C2 |
| AGENT IMPROVING ANTI-CANCER EFFECT AND CONTAINING LIPOSOMAL AGENT CONTAINING OXALIPLATIN, AND ANTI-CANCER AGENT CONTAINING LIPOSOMAL AGENT | 2009 |
|
RU2492863C2 |
| USE OF MITOXANTRONE HYDROCHLORIDE LIPOSOME | 2021 |
|
RU2821030C1 |
| LIPOSOMAL COMPOSITION AND PHARMACEUTICAL COMPOSITION | 2018 |
|
RU2734900C1 |
| LIPOSOMAL COMPOSITION AND METHOD OF OBTAINING THEREOF | 2011 |
|
RU2577683C2 |
